Datasets:

Gflorent
/

deepseek-ocr-artifacts-test-00

+{
+  "generated_at": "2025-11-11T16:37:00.361811Z",
+  "stage": "extract",
+  "dataset": {
+    "name": "HuggingFaceM4/FineVision",
+    "config": "olmOCR-mix-0225-documents",
+    "split": "train"
+  },
+  "model": {
+    "served_model_name": "deepseek-ocr",
+    "prompt": "<image>\n<|grounding|>Convert this document to Markdown.",
+    "max_tokens": 3584,
+    "temperature": 0.4
+  },
+  "inference": {
+    "max_batch_size": 8,
+    "max_concurrency": 4,
+    "request_timeout": 120,
+    "max_retries": 3,
+    "retry_backoff_seconds": 2.0,
+    "max_retry_wait_seconds": 60.0
+  },
+  "documents": [
+    {
+      "sample_id": "sample_00000",
+      "dataset_index": 0,
+      "document_path": "sample_00000/document.md",
+      "raw_response_path": "sample_00000/raw_response.md",
+      "source_image_path": "sample_00000/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00001",
+      "dataset_index": 1,
+      "document_path": "sample_00001/document.md",
+      "raw_response_path": "sample_00001/raw_response.md",
+      "source_image_path": "sample_00001/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00002",
+      "dataset_index": 2,
+      "document_path": "sample_00002/document.md",
+      "raw_response_path": "sample_00002/raw_response.md",
+      "source_image_path": "sample_00002/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00003",
+      "dataset_index": 3,
+      "document_path": "sample_00003/document.md",
+      "raw_response_path": "sample_00003/raw_response.md",
+      "source_image_path": "sample_00003/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00004",
+      "dataset_index": 4,
+      "document_path": "sample_00004/document.md",
+      "raw_response_path": "sample_00004/raw_response.md",
+      "source_image_path": "sample_00004/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00005",
+      "dataset_index": 5,
+      "document_path": "sample_00005/document.md",
+      "raw_response_path": "sample_00005/raw_response.md",
+      "source_image_path": "sample_00005/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00006",
+      "dataset_index": 6,
+      "document_path": "sample_00006/document.md",
+      "raw_response_path": "sample_00006/raw_response.md",
+      "source_image_path": "sample_00006/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00007",
+      "dataset_index": 7,
+      "document_path": "sample_00007/document.md",
+      "raw_response_path": "sample_00007/raw_response.md",
+      "source_image_path": "sample_00007/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00008",
+      "dataset_index": 8,
+      "document_path": "sample_00008/document.md",
+      "raw_response_path": "sample_00008/raw_response.md",
+      "source_image_path": "sample_00008/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00009",
+      "dataset_index": 9,
+      "document_path": "sample_00009/document.md",
+      "raw_response_path": "sample_00009/raw_response.md",
+      "source_image_path": "sample_00009/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00010",
+      "dataset_index": 10,
+      "document_path": "sample_00010/document.md",
+      "raw_response_path": "sample_00010/raw_response.md",
+      "source_image_path": "sample_00010/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00011",
+      "dataset_index": 11,
+      "document_path": "sample_00011/document.md",
+      "raw_response_path": "sample_00011/raw_response.md",
+      "source_image_path": "sample_00011/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00012",
+      "dataset_index": 12,
+      "document_path": "sample_00012/document.md",
+      "raw_response_path": "sample_00012/raw_response.md",
+      "source_image_path": "sample_00012/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00013",
+      "dataset_index": 13,
+      "document_path": "sample_00013/document.md",
+      "raw_response_path": "sample_00013/raw_response.md",
+      "source_image_path": "sample_00013/source.png",
+      "figures": [
+        {
+          "figure_id": "sample_00013_fig01",
+          "label": "image",
+          "image_path": "sample_00013/figures/sample_00013_fig01.png",
+          "document_relative_path": "figures/sample_00013_fig01.png",
+          "bounding_box_norm": {
+            "x1": 0.09176470588235294,
+            "y1": 0.025454545454545455,
+            "x2": 0.6909803921568628,
+            "y2": 0.1206060606060606
+          },
+          "bounding_box_norm_list": [
+            [
+              91.67294117647059,
+              25.42909090909091,
+              690.289411764706,
+              120.48545454545454
+            ]
+          ],
+          "bounding_box_pixels": {
+            "x1": 117,
+            "y1": 42,
+            "x2": 881,
+            "y2": 199
+          },
+          "description": null
+        }
+      ]
+    },
+    {
+      "sample_id": "sample_00014",
+      "dataset_index": 14,
+      "document_path": "sample_00014/document.md",
+      "raw_response_path": "sample_00014/raw_response.md",
+      "source_image_path": "sample_00014/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00015",
+      "dataset_index": 15,
+      "document_path": "sample_00015/document.md",
+      "raw_response_path": "sample_00015/raw_response.md",
+      "source_image_path": "sample_00015/source.png",
+      "figures": [
+        {
+          "figure_id": "sample_00015_fig01",
+          "label": "image",
+          "image_path": "sample_00015/figures/sample_00015_fig01.png",
+          "document_relative_path": "figures/sample_00015_fig01.png",
+          "bounding_box_norm": {
+            "x1": 0.04470588235294118,
+            "y1": 0.05757575757575758,
+            "x2": 0.4768627450980392,
+            "y2": 0.2606060606060606
+          },
+          "bounding_box_norm_list": [
+            [
+              44.66117647058824,
+              57.51818181818182,
+              476.38588235294117,
+              260.3454545454546
+            ]
+          ],
+          "bounding_box_pixels": {
+            "x1": 57,
+            "y1": 95,
+            "x2": 608,
+            "y2": 430
+          },
+          "description": null
+        }
+      ]
+    },
+    {
+      "sample_id": "sample_00016",
+      "dataset_index": 16,
+      "document_path": "sample_00016/document.md",
+      "raw_response_path": "sample_00016/raw_response.md",
+      "source_image_path": "sample_00016/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00017",
+      "dataset_index": 17,
+      "document_path": "sample_00017/document.md",
+      "raw_response_path": "sample_00017/raw_response.md",
+      "source_image_path": "sample_00017/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00018",
+      "dataset_index": 18,
+      "document_path": "sample_00018/document.md",
+      "raw_response_path": "sample_00018/raw_response.md",
+      "source_image_path": "sample_00018/source.png",
+      "figures": []
+    },
+    {
+      "sample_id": "sample_00019",
+      "dataset_index": 19,
+      "document_path": "sample_00019/document.md",
+      "raw_response_path": "sample_00019/raw_response.md",
+      "source_image_path": "sample_00019/source.png",
+      "figures": []
+    }
+  ],
+  "failures": []
+}

stage1/sample_00000/document.md ADDED Viewed

	@@ -0,0 +1,45 @@

+21 April 2023 Accepted: 03 June 2023 Published: 07 June 2023
+## Ethics approval and consent to participate
+The study was conducted in accordance with the ethical principles of the Declaration of Helsinki (2013). Ethical approval was obtained from Sakhiya Skin Clinic, Surat, Gujarat, India. (Approval No: 2023/06). Consent forms were signed by patient. He was informed that he had the right to withdraw from the study at any time without any consequences. All pictures reported in this case- report study belong to Sakhiya Skin Clinic, Surat- 395003, Gujarat, India.
+## Consent for publication
+Not applicable
+## Competing interest
+The authors declare that they have no competing interests.
+## Open Access
+This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article unless otherwise stated.
+## Author Details
+1Department of Dermatology, Sakhiya Skin Clinic, Surat, Gujarat, India. 2Department of Medical Writing, Sakhiya Skin Clinic, Surat, Gujarat, India
+## Article Info
+Received: 21 April 2023 Accepted: 03 June 2023 Published: 07 June 2023
+## References
+1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012 Feb;45(1):7-35. doi 10.3109/08916934.2011.606444.
+2. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977 Sep;113(9):1236-41. doi: 10.1001/archderm.1977.016400900084013.
+3. Pasricha JS, Gupta R. Pulse therapy with dexamethasonecyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984;50:199-203.
+4. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996 Sep;132(2):203-12.
+5. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. Feb 2001;66(2):142-4. doi: 10.1002/1096- 8652(200102)66:2<142::AID- AJH1032>3.0. CO;2-0.
+6. Food and Drug Administration. Rituxan label; 2012 [cited Feb 2, 2021]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012 /103705s5373lbl.pdf.
+7. Belgi AS, Azeze M, Hoyle C, Williams REA. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2006 Jan;31(1):143. doi: 10.1111/j.1365- 2230.2005.01941. x.
+8. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007 Feb;156(2):352-6. doi: 10.1111/j.1365- 2133.2006.07646. x.
+9. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatol Treat. 2007 Jan;18(5):312-4. doi: 10.1080/09546630701323988.
+10. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365- 4632.2008.03423. x.
+11. Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011 Nov;65(5):1064-5. doi: 10.1016/j.jaad.2010.06.033.
+12. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365- 2133.2011.10663. x.
+13. Craythorne E, Du Vivier A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid—refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011 Sep;40(8):616-20. doi: 10.1111/j.1600- 0714.2011.01017. x.
+14. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011Sep;165(3):646-51. doi: 10.1111/j.1365- 2133.2011.10411. x.
+15. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011 Sep;65(3):552-8. doi: 10.1016/j.jaad.2010.07.032.
+16. Investor update. Basel; June 12, 2019. [cited Feb 5, 2021]. Available from: https://www.roche.com/investors/updates/inv- update- 2019- 06- 12. htm.

stage1/sample_00000/raw_response.md ADDED Viewed

	@@ -0,0 +1,60 @@

+21 April 2023 Accepted: 03 June 2023 Published: 07 June 2023
+sub_title[[94, 87, 366, 100]]
+## Ethics approval and consent to participate
+text[[93, 100, 481, 202]]
+The study was conducted in accordance with the ethical principles of the Declaration of Helsinki (2013). Ethical approval was obtained from Sakhiya Skin Clinic, Surat, Gujarat, India. (Approval No: 2023/06). Consent forms were signed by patient. He was informed that he had the right to withdraw from the study at any time without any consequences. All pictures reported in this case- report study belong to Sakhiya Skin Clinic, Surat- 395003, Gujarat, India.
+sub_title[[94, 216, 247, 228]]
+## Consent for publication
+text[[93, 229, 188, 241]]
+Not applicable
+sub_title[[94, 255, 218, 269]]
+## Competing interest
+text[[93, 269, 445, 282]]
+The authors declare that they have no competing interests.
+sub_title[[93, 295, 176, 307]]
+## Open Access
+text[[93, 308, 481, 432]]
+This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article unless otherwise stated.
+sub_title[[93, 447, 192, 459]]
+## Author Details
+text[[93, 460, 460, 513]]
+1Department of Dermatology, Sakhiya Skin Clinic, Surat, Gujarat, India. 2Department of Medical Writing, Sakhiya Skin Clinic, Surat, Gujarat, India
+sub_title[[93, 528, 170, 539]]
+## Article Info
+text[[93, 541, 244, 579]]
+Received: 21 April 2023 Accepted: 03 June 2023 Published: 07 June 2023
+sub_title[[93, 594, 165, 606]]
+## References
+text[[93, 607, 481, 786]]
+1. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012 Feb;45(1):7-35. doi 10.3109/08916934.2011.606444.
+2. Lever WF, Schaumburg-Lever G. Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975. Arch Dermatol. 1977 Sep;113(9):1236-41. doi: 10.1001/archderm.1977.016400900084013.
+3. Pasricha JS, Gupta R. Pulse therapy with dexamethasonecyclophosphamide in pemphigus. Indian J Dermatol Venereol Leprol. 1984;50:199-203.
+4. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol. 1996 Sep;132(2):203-12.
+text[[513, 71, 904, 782]]
+5. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. Feb 2001;66(2):142-4. doi: 10.1002/1096- 8652(200102)66:2<142::AID- AJH1032>3.0. CO;2-0.
+6. Food and Drug Administration. Rituxan label; 2012 [cited Feb 2, 2021]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012 /103705s5373lbl.pdf.
+7. Belgi AS, Azeze M, Hoyle C, Williams REA. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2006 Jan;31(1):143. doi: 10.1111/j.1365- 2230.2005.01941. x.
+8. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007 Feb;156(2):352-6. doi: 10.1111/j.1365- 2133.2006.07646. x.
+9. Barrera MV, Mendiola MV, Bosch RJ, Herrera E. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris. J Dermatol Treat. 2007 Jan;18(5):312-4. doi: 10.1080/09546630701323988.
+10. Faurschou A, Gniadecki R. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365- 4632.2008.03423. x.
+11. Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011 Nov;65(5):1064-5. doi: 10.1016/j.jaad.2010.06.033.
+12. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012 Feb;166(2):405-12. doi: 10.1111/j.1365- 2133.2011.10663. x.
+13. Craythorne E, Du Vivier A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid—refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011 Sep;40(8):616-20. doi: 10.1111/j.1600- 0714.2011.01017. x.
+14. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011Sep;165(3):646-51. doi: 10.1111/j.1365- 2133.2011.10411. x.
+15. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011 Sep;65(3):552-8. doi: 10.1016/j.jaad.2010.07.032.
+16. Investor update. Basel; June 12, 2019. [cited Feb 5, 2021]. Available from: https://www.roche.com/investors/updates/inv- update- 2019- 06- 12. htm.

stage1/sample_00000/source.png ADDED Viewed

Git LFS Details

SHA256: 60a41e09f2f1ab697c301b09d29ed67685ca8e56cd02c2b3f39b6004cad58885
Pointer size: 131 Bytes
Size of remote file: 529 kB

stage1/sample_00001/document.md ADDED Viewed

	@@ -0,0 +1 @@

+ 3- month history of painful ulcerated lesions in the oral cavity. On enquiring about the patient's history, we came to know that initially, the patient had difficulty chewing food and the severity increased gradually. The ulcerations caused considerable discomfort, affecting his normal oral functions. Subsequently, fluid-filled lesions developed involving the scalp, trunk, limbs, and axilla. Lesions were increasing in size and number and had little tendency to heal. Blisters were flaccid and burst on their own to form erosions within 2-3 days. Medical and family history was non- contributory. No history of fever, joint pain, malaise, and photosensitivity. He had weak oral hygiene due to the bad habit of taking betel quid with tobacco five times a day and smoking seven- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

stage1/sample_00001/raw_response.md ADDED Viewed

	@@ -0,0 +1 @@

stage1/sample_00001/source.png ADDED Viewed

Git LFS Details

SHA256: f95e2713a33ee44cdd553c81d6461aff91057781e4497be87f7256e3366f450a
Pointer size: 132 Bytes
Size of remote file: 1.19 MB

stage1/sample_00002/document.md ADDED Viewed

	@@ -0,0 +1,16 @@

+2645-9248 Journal homepage: www.jidhealth.com Open A ccess Original Article A case report on generalized pemphigus vulgaris treated with rituximaba J agdish J adavbhai S akhiya<sup>1</sup>*, Dhruv J agdish S akhiya<sup>1</sup>, J ashmine Mukeshbhai Gandhi<sup>1</sup>, F eral R avi Daruwala<sup>2</sup>
+## Abstract
+Background: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris.
+Case presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed.
+Conclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails.
+Keywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India
+## Background
+text[[94, 609, 485, 833], [511, 595, 904, 903]]
+The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of high- dose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive

stage1/sample_00002/raw_response.md ADDED Viewed

	@@ -0,0 +1,22 @@

+2645-9248 Journal homepage: www.jidhealth.com Open A ccess Original Article A case report on generalized pemphigus vulgaris treated with rituximaba J agdish J adavbhai S akhiya<sup>1</sup>*, Dhruv J agdish S akhiya<sup>1</sup>, J ashmine Mukeshbhai Gandhi<sup>1</sup>, F eral R avi Daruwala<sup>2</sup>
+sub_title[[100, 351, 174, 364]]
+## Abstract
+text[[100, 366, 875, 404]]
+Background: Pemphigus vulgaris has an obscure etiology; the presence of autoantibodies is coherent with an autoimmune disease. Rituximab a monoclonal antibody that specifically targets the CD20 antigen of B lymphocytes, has arisen as a novel treatment approach for pemphigus vulgaris.
+text[[100, 412, 885, 474]]
+Case presentation: A 39- year- old male patient presented with a three- month history of mouth ulcers, poor oral hygiene accompanied with heavy tobacco smoking and alcohol consumption. He was diagnosed with pemphigus vulgaris. The disease gradually progressed to involve other body parts. The patient had shown partial improvement after conventional therapy (oral cefuroxime, oral prednisolone with azathioprine) and was later on successfully treated with rituximab. After 90 days of follow- up, no future recurrence was observed.
+text[[100, 484, 893, 512]]
+Conclusion: With this case, the authors would like to aware other clinicians of the potential use of rituximab in treating pemphigus vulgaris, especially when the conventional therapy fails.
+text[[100, 522, 813, 556]]
+Keywords: Autoantibodies; Pemphigus, Rituximab, Oral Hygiene, Ulceration, Tobacco Smoking, Alcohol consumption, India
+sub_title[[94, 593, 192, 608]]
+## Background
+text[[94, 609, 485, 833], [511, 595, 904, 903]]
+The term pemphigus implies a group of autoimmune, mucocutaneous blistering diseases, in which the keratinocyte antigens are the target of the autoantibodies, prompting acantholysis and the formation of blisters. Main variants of pemphigus include pemphigus vulgaris (PV) and pemphigus foliaceus (PF). PV is the most common subtype and represents well over \(80\%\) of cases. As being a serious and potentially lifethreatening condition, early treatment is of utmost importance [1]. The advent of corticosteroids in the amelioration of pemphigus has dramatically changed the outlook of this perpetually disastrous disease; thus, corticosteroids have become the cornerstone of pemphigus therapy. One case reported favorable outcomes with combined therapy of high- dose corticosteroids and other immunosuppressants. However, such a high dose of corticosteroids can cause serious adverse events such as several metabolic problems, global reduction of immune system efficacy, antecedent risk of serious infections, and mortality [2]. To overcome these long- term events, Psaricha and Gupta introduced dexamethasone cyclophosphamide pulse (DCP) therapy in 1984 [3]. Later on, DCP and oral corticosteroids with or without adjuvant immunosuppressants (azathioprine, cyclophosphamide, mycophenolate mofetil, and cyclosporine) have emerged as the backbone of pemphigus treatment, however, they are associated with the high death rate in pemphigus [4]. With these conventional treatments, some patients fail to improve or some have contraindications for their usage, or some encounter relapse. Hence, advanced research has continuously been going on for finding newer molecules in pemphigus. In 2001, Heizmann et al. [5] first used rituximab for the therapy of autoimmune bullous diseases. He reported a case of paraneoplastic pemphigus favorably managed with rituximab, since then there was a drastic development in the pemphigus treatment era. Rituximab chimeric monoclonal antibody selectively acts on the CD20 expressing B cells, which are known to secrete auto- antibodies targeting the epidermal desmogleins (DSG). It has been used nearly in one million patients for treating lymphoma worldwide. Recently, rituximab has been approved for rheumatoid arthritis that is unresponsive

stage1/sample_00002/source.png ADDED Viewed

Git LFS Details

SHA256: 06f0273ec5ceb3ff25ef406fe9063fa4f7d1d4deaa059b8ba92af4a1b720bcc0
Pointer size: 131 Bytes
Size of remote file: 529 kB

stage1/sample_00003/document.md ADDED Viewed

	@@ -0,0 +1 @@

+ 1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 13) 14) 15) 16) 17) 18) 19) 20) 21) 22) 23) 24) 25) 26) 27) 28) 29) 30) 31) 32) 33) 34) 35) 36) 37) 38) 39) 40) 41) 42) 43) 44) 45) 46) 47) 48) 49) 50) 51) 52) 53) 54) 55) 56) 57) 58) 59) 60) 61) 62) 63) 64) 65) 66) 67) 68) 69) 70) 71) 72) 73) 74) 75) 76) 77) 78) 79) 80) 81) 82) 83) 84) 85) 86) 87) 88) 89) 90) 91) 92) 93) 94) 95) 96) 97) 98) 99) 100) 101) 102) 103) 104) 105) 106) 107) 108) 109) 110) 111) 112) 113) 114) 115) 116) 117) 118) 119) 120) 121) 122) 123) 124) 125) 126) 127) 128) 129) 130) 131) 132) 133) 134) 135) 136) 137) 138) 139) 140) 141) 142) 143) 144) 145) 146) 147) 148) 149) 150) 151) 152) 153) 154) 155) 156) 157) 158) 159) 160) 161) 162) 163) 164) 165) 166) 167) 168) 169) 170) 171) 172) 173) 174) 175) 176) 177) 178) 179) 180) 181) 182) 183) 184) 185) 186) 187) 188) 189) 190) 191) 192) 193) 194) 195) 196) 197) 198) 199) 200) 201) 202) 203) 204) 205) 206) 207) 208) 209) 210) 211) 212) 213) 214) 215) 216) 217) 218) 219) 220) 221) 222) 223) 224) 225) 226) 227) 228) 229) 230) 231) 232) 233) 234) 235) 236) 237) 238) 239) 240) 241) 242) 243) 244) 245) 246) 247) 248) 249) 250) 251) 252) 253) 254) 255) 256) 257) 258) 259) 260) 261) 262) 263) 264) 265) 266) 267) 268) 269) 270) 271) 272) 273) 274) 275) 276) 277) 278) 279) 280) 281) 282) 283) 284) 285) 286) 287) 288) 289) 290) 291) 292) 293) 294) 295) 296) 297) 298) 299) 300) 301) 302) 303) 304) 305) 306) 307) 308) 309) 310) 311) 312) 313) 314) 315) 316) 317) 318) 319) 320) 321) 322) 323) 324) 325) 326) 327) 328) 329) 330) 331) 332) 333) 334) 335) 336) 337) 338) 339) 340) 341) 342) 343) 344) 345) 346) 347) 348) 349) 350) 351) 352) 353) 354) 355) 356) 357) 358) 359) 360) 361) 362) 363) 364) 365) 366) 367) 368) 369) 370) 371) 372) 373) 374) 375) 376) 377) 378) 379) 380) 381) 382) 383) 384) 385) 386) 387) 388) 389) 390) 391) 392) 393) 394) 395) 396) 397) 398) 399) 400) 401) 402) 403) 404) 405) 406) 407) 408) 409) 410) 411) 412) 413) 414) 415) 416) 417) 418) 419) 420) 421) 422) 423) 424) 425) 426) 427) 428) 429) 430) 431) 432) 433) 434) 435) 436) 437) 438) 439) 440) 441) 442) 443) 444) 445) 446) 447) 448) 449) 450) 451) 452) 453) 454) 455) 456) 457) 458) 459) 460) 461) 462) 463) 464) 465) 466) 467) 468) 469) 470) 471) 472) 473) 474) 475) 476) 477) 478) 479) 480) 481) 482) 483) 484) 485) 486) 487) 488) 489) 490) 491) 492) 493) 494) 495) 496) 497) 498) 499) 500) 501) 502) 503) 504) 505) 506) 507) 508) 509) 510) 511) 512) 513) 514) 515) 516) 517) 518) 519) 520) 521) 522) 523) 524) 525) 526) 527) 528) 529) 530) 531) 532) 533) 534) 535) 536) 537) 538) 539) 540) 541) 542) 543) 544) 545) 546) 547) 548) 549) 550) 551) 552) 553) 554) 555) 556) 557) 558) 559) 560) 561) 562) 563) 564) 565) 566) 567) 568) 569) 570) 571) 572) 573) 574) 575) 576) 577) 578) 579) 580) 581) 582) 583) 584) 585) 586) 587) 588) 589) 590) 591) 592) 593) 594) 595) 596) 597) 598) 599) 600) 601) 602) 603) 604) 605) 606) 607) 608) 609) 610) 611) 612) 613) 614) 615) 616) 617) 618) 619) 620) 621) 622) 623) 624) 625) 626) 627) 628) 629) 630) 631) 632) 633) 634) 635) 636) 637) 638) 639) 640) 641) 642) 643) 644) 645) 646) 647) 648) 649) 650) 651) 652) 653) 654) 655) 656) 657) 658) 659) 660) 661) 662) 663) 664) 665) 666) 667) 668) 669) 670) 671) 672) 673) 674) 675) 676) 677) 678) 679) 680) 681) 682) 683) 684) 685) 686) 687) 688) 689) 690) 691) 692) 693) 694) 695) 696) 697) 698) 699) 700) 701) 702) 703) 704) 705) 706) 707) 708) 709) 710) 711) 712) 713) 714) 715) 716) 717) 718) 719) 720) 721) 722) 723) 724) 725) 726) 727) 728) 729) 730) 731) 732) 733) 734) 735) 736) 737) 738) 739) 740) 741) 742) 743) 744) 745) 746) 747) 748) 749) 750) 751) 752) 753) 754) 755) 756) 757) 758) 759) 760) 761) 762) 763) 764) 765) 766) 767) 768) 769) 770) 771) 772) 773) 774) 775) 776) 777) 778) 779) 780) 781) 782) 783) 784) 785) 786) 787) 788) 789) 790) 791) 792) 793) 794) 795) 796) 797) 798) 799) 800) 801) 802) 803) 804) 805) 806) 807) 808) 809) 810) 811) 812) 813) 814) 815) 816) 817) 818) 819) 820) 821) 822) 823) 824) 825) 826) 827) 828) 829) 830) 831) 832) 833) 834) 835) 836) 837) 838) 839) 840) 841) 842) 843) 844) 845) 846) 847) 848) 849) 850) 851) 852) 853) 854) 855) 856) 857) 858) 859) 860) 861) 862) 863) 864) 865) 866) 867) 868) 869) 870) 871) 872) 873) 874) 875) 876) 877) 878) 879) 880) 881) 882) 883) 884) 885) 886) 887) 888) 889) 890) 891) 892) 893) 894) 895) 896) 897) 898) 899) 900) 901) 902) 903) 904) 905) 906) 907) 908) 909) 910) 911) 912) 913) 914) 915) 916) 917) 918) 919) 920) 921) 922) 923) 924) 925) 926) 927) 928) 929) 930) 931) 932) 933) 934) 935) 936) 937) 938) 939) 940) 941) 942) 943) 944) 945) 946) 947) 948) 949) 950) 951) 952) 953) 954) 955) 956) 957) 958) 959) 960) 961) 962) 963) 964) 965) 966) 967) 968) 969) 970) 971) 972) 973) 974) 975) 976) 977) 978) 979) 980) 981) 982) 983) 984) 985) 986) 987) 988) 989) 990) 991) 992) 993) 994) 995) 996) 997) 998) 999) 1000) 1001) 1002) 1003) 1004) 1005) 1006) 1007) 1008) 1009) 1010) 1011) 1012) 1013) 1014) 1015) 1016) 1017) 1018) 1019) 1020) 1021) 1022) 1023) 1024) 1025) 1026) 1027) 1028) 1029) 1030) 1031) 1032) 1033) 1034) 1035) 1036) 1037) 1038) 1039) 1040) 1041) 1042) 1043) 1044)

stage1/sample_00003/raw_response.md ADDED Viewed

	@@ -0,0 +1 @@

stage1/sample_00003/source.png ADDED Viewed

Git LFS Details

SHA256: 99d3a34b704362461d791f6cc551238ae0452e6f6ebda3f237b2e154d75f770e
Pointer size: 131 Bytes
Size of remote file: 558 kB

stage1/sample_00004/document.md ADDED Viewed

	@@ -0,0 +1,17 @@

+The parametric equations for a projectile with constant gravity g:
+\[ x = v_0 t \cos \theta + x_0 \]
+\[ y = -\frac{1}{2} gt^2 + v_0 t \sin \theta + y_0 \]
+ex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find:
+1. \(\vec{r}(t)\)
+2. the maximum altitude attained
+3. the range of the shell
+4. the speed on impact
+5. the horizontal distance when \(y = 2240\) ft.

stage1/sample_00004/raw_response.md ADDED Viewed

	@@ -0,0 +1,26 @@

+text[[90, 80, 861, 107]]
+The parametric equations for a projectile with constant gravity g:
+equation[[153, 109, 425, 140]]
+\[ x = v_0 t \cos \theta + x_0 \]
+equation[[152, 155, 566, 228]]
+\[ y = -\frac{1}{2} gt^2 + v_0 t \sin \theta + y_0 \]
+text[[89, 255, 867, 307]]
+ex. A shell is fired from ground level with an initial speed of 768 ft/sec. at an angle of 30°. Find:
+text[[93, 309, 183, 352]]
+1. \(\vec{r}(t)\)
+text[[91, 357, 484, 382]]
+2. the maximum altitude attained
+text[[91, 384, 372, 408]]
+3. the range of the shell
+text[[91, 411, 360, 435]]
+4. the speed on impact
+text[[91, 437, 605, 462]]
+5. the horizontal distance when \(y = 2240\) ft.

stage1/sample_00004/source.png ADDED Viewed

Git LFS Details

SHA256: 5284438a4577b88656ac76bf9832a40c857ec3877502750776e7561f7f303d20
Pointer size: 131 Bytes
Size of remote file: 101 kB

stage1/sample_00005/document.md ADDED Viewed

	@@ -0,0 +1,3 @@


1	+ An electron in a TV tube is beamed horizontally at a speed of 5 x \(10^6\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used?
2	+
3	+ a. \(y = -4.9t^2\) b. \(y = -4.9t^2 - 5\times 10^6t\) c. \(5\times 10^6t = 4\) d. \(5\times 10^6t = 40\)

stage1/sample_00005/raw_response.md ADDED Viewed

	@@ -0,0 +1,4 @@

+An electron in a TV tube is beamed horizontally at a speed of 5 x \(10^6\) m/sec. toward the face of the tube 40 cm away. To determine how far the electron drops before it hits, which equation would be used?
+text[[88, 213, 419, 355]]
+a. \(y = -4.9t^2\) b. \(y = -4.9t^2 - 5\times 10^6t\) c. \(5\times 10^6t = 4\) d. \(5\times 10^6t = 40\)

stage1/sample_00005/source.png ADDED Viewed

Git LFS Details

SHA256: ef037a0ef4d37457a67b7c975fb63b5996a68867199c12b4c55732fcbc0da39c
Pointer size: 130 Bytes
Size of remote file: 79.4 kB

stage1/sample_00006/document.md ADDED Viewed

	@@ -0,0 +1 @@

+ 4: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1: 1:

stage1/sample_00006/raw_response.md ADDED Viewed

	@@ -0,0 +1 @@

stage1/sample_00006/source.png ADDED Viewed

Git LFS Details

SHA256: 2cd4ea5cf564a827d25191d3e1a6281f4447afd1265ec4d31eb2d81f52b33fcf
Pointer size: 131 Bytes
Size of remote file: 358 kB

stage1/sample_00007/document.md ADDED Viewed

	@@ -0,0 +1 @@

+ 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142. 143. 144. 145. 146. 147. 148. 149. 150. 151. 152. 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177. 178. 179. 180. 181. 182. 183. 184. 185. 186. 187. 188. 189. 190. 191. 192. 193. 194. 195. 196. 197. 198. 199. 200. 201. 202. 203. 204. 205. 206. 207. 208. 209. 210. 211. 212. 213. 214. 215. 216. 217. 218. 219. 220. 221. 222. 223. 224. 225. 226. 227. 228. 229. 230. 231. 232. 233. 234. 235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246. 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273. 274. 275. 276. 277. 278. 279. 280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291. 292. 293. 294. 295. 296. 297. 298. 299. 300. 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317. 318. 319. 320. 321. 322. 323. 324. 325. 326. 327. 328. 329. 330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354. 355. 356. 357. 358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383. 384. 385. 386. 387. 388. 389. 390. 391. 392. 393. 394. 395. 396. 397. 398. 399. 400. 401. 402. 403. 404. 405. 406. 407. 408. 409. 410. 411. 412. 413. 414. 415. 416. 417. 418. 419. 420. 421. 422. 423. 424. 425. 426. 427. 428. 429. 430. 431. 432. 433. 434. 435. 436. 437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458. 459. 460. 461. 462. 463. 464. 465. 466. 467. 468. 469. 470. 471. 472. 473. 474. 475. 476. 477. 478. 479. 480. 481. 482. 483. 484. 485. 486. 487. 488. 489. 490. 491. 492. 493. 494. 495. 496. 497. 498. 499. 500. 501. 502. 503. 504. 505. 506. 507. 508. 509. 510. 511. 512. 513. 514. 515. 516. 517. 518. 519. 520. 521. 522. 523. 524. 525. 526. 527. 528. 529. 530. 531. 532. 533. 534. 535. 536. 537. 538. 539. 540. 541. 542. 543. 544. 545. 546. 547. 548. 549. 550. 551. 552. 553. 554. 555. 556. 557. 558. 559. 560. 561. 562. 563. 564. 565. 566. 567. 568. 569. 570. 571. 572. 573. 574. 575. 576. 577. 578. 579. 580. 581. 582. 583. 584. 585. 586. 587. 588. 589. 590. 591. 592. 593. 594. 595. 596. 597. 598. 599. 600. 601. 602. 603. 604. 605. 606. 607. 608. 609. 610. 611. 612. 613. 614. 615. 616. 617. 618. 619. 620. 621. 622. 623. 624. 625. 626. 627. 628. 629. 630. 631. 632. 633. 634. 635. 636. 637. 638. 639. 640. 641. 642. 643. 644. 645. 646. 647. 648. 649. 650. 651. 652. 653. 654. 655. 656. 657. 658. 659. 660. 661. 662. 663. 664. 665. 666. 667. 668. 669. 670. 671. 672. 673. 674. 675. 676. 677. 678. 679. 680. 681. 682. 683. 684. 685. 686. 687. 688. 689. 690. 691. 692. 693. 694. 695. 696. 697. 698. 699. 700. 701. 702. 703. 704. 705. 706. 707. 708. 709. 710. 711. 712. 713. 714. 715. 716. 717. 718. 719. 720. 721. 722. 723. 724. 725. 726. 727. 728. 729. 730. 731. 732. 733. 734. 735. 736. 737. 738. 739. 740. 741. 742. 743. 744. 745. 746. 747. 748. 749. 750. 751. 752. 753. 754. 755. 756. 757. 758. 759. 760. 761. 762. 763. 764. 765. 766. 767. 768. 769. 770. 771. 772. 773. 774. 775. 776. 777. 778. 779. 780. 781. 782. 783. 784. 785. 786. 787. 788. 789. 790. 791. 792. 793. 794. 795. 796. 797. 798. 799. 800. 801. 802. 803. 804. 805. 806. 807. 808. 809. 810. 811. 812. 813. 814. 815. 816. 817. 818. 819. 820. 821. 822. 823. 824. 825. 826. 827. 828. 829. 830. 831. 832. 833. 834. 835. 836. 837. 838. 839. 840. 841. 842. 843. 844. 845. 846. 847. 848. 849. 850. 851. 852. 853. 854. 855. 856. 857. 858. 859. 860. 861. 862. 863. 864. 865. 866. 867. 868. 869. 870. 871. 872. 873. 874. 875. 876. 877. 878. 879. 880. 881. 882. 883. 884. 885. 886. 887. 888. 889. 890. 891. 892. 893. 894. 895. 896. 897. 898. 899. 900. 901. 902. 903. 904. 905. 906. 907. 908. 909. 910. 911. 912. 913. 914. 915. 916. 917. 918. 919. 920. 921. 922. 923. 924. 925. 926. 927. 928. 929. 930. 931. 932. 933. 934. 935. 936. 937. 938. 939. 940. 941. 942. 943. 944. 945. 946. 947. 948. 949. 950. 951. 952. 953. 954. 955. 956. 957. 958. 959. 960. 961. 962. 963. 964. 965. 966. 967. 968. 969. 970. 971. 972. 973. 974. 975. 976. 977. 978. 979. 980. 981. 982. 983. 984. 985. 986. 987. 988. 989. 990. 991. 992. 993. 994. 995. 996. 997. 998. 999. 1000. 1001. 1002. 1003. 1004. 1005. 1006. 1007. 1008. 1009. 1010. 1011. 1012. 1013. 1014. 1015. 1016. 1017. 1018. 1019. 1020. 1021. 1022. 1023. 1024. 1025. 1026. 1027. 1028. 1029. 1030. 1031. 1032. 1033. 1034. 1035. 1036. 1037. 1038. 1039. 1040. 1041. 1042. 1043. 1044.

stage1/sample_00007/raw_response.md ADDED Viewed

	@@ -0,0 +1 @@

stage1/sample_00007/source.png ADDED Viewed

Git LFS Details

SHA256: d7f32e866dd7ee413cb3e62b2ea22633b4f7ccdfd89bb79276eb92a97b521abe
Pointer size: 131 Bytes
Size of remote file: 216 kB

stage1/sample_00008/document.md ADDED Viewed

	@@ -0,0 +1,45 @@

+1)
+Recent studies dealing with family status in the Arab world are few and sometimes contradictory. While some researchers, such as Dr. Madeeha Naser (1972), assume that 75% of Iraqi families belong to the extended type grouping three generations living under one roof(2), Dr. Sana Khawli's investigation, condensed in Al-Raida (no. 9, vol. II, p. 15), leads her to conclude that the Arab family is evolving into a non-isolated nuclear family.
+Some researchers adopt a middle course by recognizing the existence of differences between country and town regarding family type and affirming that the extended family exists in a larger proportion in the country than in town and city. Good, another sociologist, asserts that for economic and other reasons, the extended family has not been the rule in Arab countries. Peterson says that demographic factors have prevented the extensive spread of the extended family in Egypt and that the large family of six members or more formed 40% of Egyptian families since the beginning of the twentieth century.
+A study prepared by Dr. Fahd al- Thaqeb aims to show that even if economic and demographic conditions should favor the spread of the extended family, as is the case in Kuwait, this family type is bound to remain a minority.
+This study is based on statistics derived from interviews between 1965 and 1970 with a random sample of Kuwaiti families representing various social levels.
+## Family Size
+Between 1965 and 1970, the majority of families in Kuwait were made up of six or more members per family. This proportion decreased among university graduates from 67.4% in 1965 to 56.9% in 1970. The data reveal that the number of family members tends to decrease in proportion with the cultural, economic and social status of the family. For example, while 33% of family heads with secondary education have limited the number of their families to five or less, only 12% of illiterate family heads have adhered to this number.
+Large- sized families are characteristic of higher middle and lower middle classes. Small- sized families of 1- 5 members exist at the rate of 38% in less privileged classes, while 72% of the lower middle class are made up of eight or more each.
+## Family Structure
+Three family types have been singled out: the nuclear, the quasi- extended and the extended family. The first
+(1) Condensed from Dr. Fahd Al-Thaqeb, "Size and Structure of the Arab and Kuwaiti Family," Journal of Social Sciences, No 12, Year IV, July 1976 (Arabic), pp. 81-91.
+(2) Ibid. p. 81.
+comprises the parents and children; the third includes two or more families living in the same house, joined by blood ties. The quasi- extended family is a small sized extended family.
+In Kuwait, the nuclear family forms 59.2%, the quasi- extended 18.4%, and the extended family 22.4%.
+The size of the family is not a sound indicator of its type, though it may have some connection with it. It was found that only 26% of the nuclear families interviewed were made up of six members each, while 70% of them had 6- 12 members per unit.
+The study has shown that the nuclear family, while it is not the ideal type, is most common among urban, educated, young people and among the middle class. This type is less common in lower and lower middle class. About 31% of families of the lower class are quasi- extended while in the upper socio- economic group, the quasi- extended type reaches only 15%.
+The proportion of the extended family type is higher among illiterate groups: 30% for illiterate against 17% for university people.
+## Age of Respondents
+The family type differed according to the age of people interviewed. Around 50% of the young lived in nuclear families. Many of them lived in quasi- nuclear ones and did not break communication with their relatives. The ages of 65% of nuclear family people ranged between 30 and 39 years, while the highest proportion of the extended family type existed among those who were 50 years of age or above.
+## Conclusion
+The majority of families forming the random sample of this survey belonged to the nuclear family type. The extended family, though it should be favored by social and demographic conditions in a country like Kuwait, is likely to form a minority.
+The data show a steady increase in the average number of family members during the last few years. In 1957 the average was 6.8 per family; in 1965 it rose to 7.3; and in 1970, to 7.6. The rise is due to improved economic and demographic conditions in Kuwait. Also, the proportion of families numbering 6 or more each, rose from 66.4% in 1965 to 70.2% in 1970.
+The family size is also an indicator of the fertility rate and bears no relation to family structure. It is noteworthy that extended families joining together three generations formed only 17% of the bulk of extended families. This result coincides with Good's theory that traditional, extended families have been and remain a minority in the Arab world.

stage1/sample_00008/raw_response.md ADDED Viewed

	@@ -0,0 +1,67 @@

+1)
+text[[22, 211, 468, 320]]
+Recent studies dealing with family status in the Arab world are few and sometimes contradictory. While some researchers, such as Dr. Madeeha Naser (1972), assume that 75% of Iraqi families belong to the extended type grouping three generations living under one roof(2), Dr. Sana Khawli's investigation, condensed in Al-Raida (no. 9, vol. II, p. 15), leads her to conclude that the Arab family is evolving into a non-isolated nuclear family.
+text[[22, 320, 468, 467]]
+Some researchers adopt a middle course by recognizing the existence of differences between country and town regarding family type and affirming that the extended family exists in a larger proportion in the country than in town and city. Good, another sociologist, asserts that for economic and other reasons, the extended family has not been the rule in Arab countries. Peterson says that demographic factors have prevented the extensive spread of the extended family in Egypt and that the large family of six members or more formed 40% of Egyptian families since the beginning of the twentieth century.
+text[[22, 467, 468, 521]]
+A study prepared by Dr. Fahd al- Thaqeb aims to show that even if economic and demographic conditions should favor the spread of the extended family, as is the case in Kuwait, this family type is bound to remain a minority.
+text[[22, 521, 468, 564]]
+This study is based on statistics derived from interviews between 1965 and 1970 with a random sample of Kuwaiti families representing various social levels.
+sub_title[[22, 577, 111, 590]]
+## Family Size
+text[[22, 599, 468, 738]]
+Between 1965 and 1970, the majority of families in Kuwait were made up of six or more members per family. This proportion decreased among university graduates from 67.4% in 1965 to 56.9% in 1970. The data reveal that the number of family members tends to decrease in proportion with the cultural, economic and social status of the family. For example, while 33% of family heads with secondary education have limited the number of their families to five or less, only 12% of illiterate family heads have adhered to this number.
+text[[22, 738, 468, 806]]
+Large- sized families are characteristic of higher middle and lower middle classes. Small- sized families of 1- 5 members exist at the rate of 38% in less privileged classes, while 72% of the lower middle class are made up of eight or more each.
+sub_title[[22, 819, 153, 832]]
+## Family Structure
+text[[22, 846, 468, 873]]
+Three family types have been singled out: the nuclear, the quasi- extended and the extended family. The first
+text[[22, 896, 469, 933]]
+(1) Condensed from Dr. Fahd Al-Thaqeb, "Size and Structure of the Arab and Kuwaiti Family," Journal of Social Sciences, No 12, Year IV, July 1976 (Arabic), pp. 81-91.
+text[[23, 938, 121, 950]]
+(2) Ibid. p. 81.
+text[[523, 210, 970, 265]]
+comprises the parents and children; the third includes two or more families living in the same house, joined by blood ties. The quasi- extended family is a small sized extended family.
+text[[523, 265, 970, 293]]
+In Kuwait, the nuclear family forms 59.2%, the quasi- extended 18.4%, and the extended family 22.4%.
+text[[523, 296, 970, 363]]
+The size of the family is not a sound indicator of its type, though it may have some connection with it. It was found that only 26% of the nuclear families interviewed were made up of six members each, while 70% of them had 6- 12 members per unit.
+text[[523, 364, 970, 458]]
+The study has shown that the nuclear family, while it is not the ideal type, is most common among urban, educated, young people and among the middle class. This type is less common in lower and lower middle class. About 31% of families of the lower class are quasi- extended while in the upper socio- economic group, the quasi- extended type reaches only 15%.
+text[[523, 458, 970, 499]]
+The proportion of the extended family type is higher among illiterate groups: 30% for illiterate against 17% for university people.
+sub_title[[523, 513, 670, 526]]
+## Age of Respondents
+text[[523, 540, 970, 649]]
+The family type differed according to the age of people interviewed. Around 50% of the young lived in nuclear families. Many of them lived in quasi- nuclear ones and did not break communication with their relatives. The ages of 65% of nuclear family people ranged between 30 and 39 years, while the highest proportion of the extended family type existed among those who were 50 years of age or above.
+sub_title[[523, 664, 611, 676]]
+## Conclusion
+text[[523, 690, 970, 759]]
+The majority of families forming the random sample of this survey belonged to the nuclear family type. The extended family, though it should be favored by social and demographic conditions in a country like Kuwait, is likely to form a minority.
+text[[523, 760, 970, 853]]
+The data show a steady increase in the average number of family members during the last few years. In 1957 the average was 6.8 per family; in 1965 it rose to 7.3; and in 1970, to 7.6. The rise is due to improved economic and demographic conditions in Kuwait. Also, the proportion of families numbering 6 or more each, rose from 66.4% in 1965 to 70.2% in 1970.
+text[[523, 854, 970, 946]]
+The family size is also an indicator of the fertility rate and bears no relation to family structure. It is noteworthy that extended families joining together three generations formed only 17% of the bulk of extended families. This result coincides with Good's theory that traditional, extended families have been and remain a minority in the Arab world.

stage1/sample_00008/source.png ADDED Viewed

Git LFS Details

SHA256: f5f1a9491efacf173b223855e0ec0631cfabd4802eac6c22a4ac730fd463f1ee
Pointer size: 132 Bytes
Size of remote file: 2.3 MB

stage1/sample_00009/document.md ADDED Viewed

	@@ -0,0 +1,29 @@

+24 baseline demographics and disease characteristics. Significant \((p<0.1)\) variables in univariate were included in multivariate models. Last, multivariate models were selected based on model fit statistics (Akaike information criterion and \(\mathrm {r}^{2})\) and clinical significance. Adjusted OR and \(95\%\) CIs for selected baseline variables were calculated.
+# RESULTS
+Overall, 334 patients were randomised to treatment and received adalimumab+MTX \(\mathrm {n}=171)\) or MTX alone \(\left(\mathrm {n}=163\right)\) ,and 148 \((86.5\%)\) and 128 \((78.5\%)\) patients completed the double-blind portion of the study, respectively (figure 1).Demographics and baseline characteristics were well matched between treatment groups (table 1). The mean RA disease duration was 0.3 years, and the majority of patients had \(\geq 1\) erosion at baseline and high disease activity. The mean MTX dose during the 26-week study was \(6.2\pm 0.8\mathrm {\sim mg}/\mathrm {week}\) in the adalimumab+MTX group and \(6.6\pm 0.6\mathrm {\sim mg}/\mathrm {week}\) in the MTX alone group \((p<0.001)\) . After 26 weeks of treatment, \(34.5\%\) \((59/171)\) of adalimumab+MTX patients were receiving MTX 8 mg/week versus \(65.0\%\) (106/163) of MTX alone patients \((p<0.001)\) .
+# Radiographic progression
+Treatment with adalimumab+MTX significantly inhibited radiographic progression (figure 2A) at week 26 versus MTX alone (mean change±SD, \(1.5\pm 6.1\) vs \(2.4\pm 3.2\) , respectively; \(p<0.001)\) . Results were confirmed by an LE analysis (figure 2A). Changes in radiographic progression during 26 weeks of treatment were also assessed by a cumulative probability plot of \(\Delta \mathrm {mTSS}\)  (figure 2B). Fewer adalimumab+MTX patients exhibited radiographic progression \((\Delta \mathrm {mTSS}>0.5)\) ,with \(62.0\%\) (106/171) of patients showing no radiographic progression versus \(35.4\%\) (57/161) of MTX alone patients \((p<0.001)\) .Furthermore, only \(14.0\%\) (24/171) of adalimumab+MTX patients exhibited clinically relevant radiographic progression \((\Delta \mathrm {mTSS}>3)\) versus \(37.3\%\) (60/161) of MTX alone patients \((p<0.001)\) . In addition, a significantly higher percentage of adalimumab+MTX patients did not experience worsening \((\leq 0.5)\) in erosion score ( \(73.7\%\) (126/171)) versus MTX alone patients \((42.2\%\) (68/161); \(p<0.001)\) . In patients who lacked baseline erosive damage, the continued absence of erosions was reported in more adalimumab+MTX patients versus MTX alone patients \((9/9\) vs 2/6 patients, respectively; \(p=0.01)\) .
+# Clinical response
+A significantly higher percentage of adalimumab+MTX patients achieved ACR responses versus MTX alone patients at each assessment (figure 3A-C). Significant differences between treatment groups, observed as early as week 2, were maintained through week 26. At week 26, a significantly larger percentage of adalimumab+MTX patients versus MTX alone patients achieved ACR20, ACR50 and ACR70 (figure 3A-C) and ACR90 ( \(12.9\%\) vs \(5.5\%\) ; \(p=0.02)\)  responses. Significant differences in favour of adalimumab+MTX were also observed from week 2 to 26 for DAS28-ESR, DAS28-CRP, SDAI and CDAI (see online supplementary figure 1A-D). A larger percentage of adalimumab+MTX patients than MTX alone patients demonstrated good or moderate European League Against Rheumatism responses (figure 3D) and were in states of low disease activity or remission after 26 weeks of treatment (figure 3E). Furthermore, a significantly larger percentage of adalimumab+MTX patients versus MTX alone patients satisfied Boolean remission criteria ( \(19.3\%\) vs \(8.6\%\) , \(p=0.007)\) . Adalimumab+MTX achieved a 1.8-
+Table 1 Demographics and baseline characteristics
+<table>Parameter*Adalimumab+MTX<br>\(\left(\mathrm {n}=171\right)\)MTX \(\left(\mathrm {n}=163\right)\)\(\text {Age}\pm \mathrm {SD}\) (year)\(54.0\pm 13.1\)\(54.0\pm 13.2\)Females \(\left(\% \right)\)144 (84.2)128 (78.5)RA duration\(\pm \mathrm {SD}\) (year)\(0.3\pm 0.4\)\(0.3\pm 0.4\)Weight\(\pm \mathrm {SD}\) (kg)\(54.4\pm 9.7\)\(56.1\pm 12.3\)Previous DMARD use \(\left(\% \right)\)74 (43.3)87 (53.4)1 DMARD57 (33.3)69 (42.3)2 DMARDs17 (9.9)18 (11.0)Corticosteroid use at baseline \(\left(\% \right)\)58 (33.9)49 (30.1)RF positive \(\left(\% \right)\)146 (85.4)136 (83.4)Mean titre±SD (IU/ml)\(154.5\pm 202.3\)\(163.7\pm 362.8\)Anti-CCP positive \(\left(\% \right)\)145 (84.8)136 (83.4)Mean titre±SD (U/ml)\(386.2\pm 694.2\)\(241.3\pm 367.2\)ESR \(\left(\mathrm {mm}/\mathrm {h}\right)\)\(59.9\pm 30.1\)\(61.8\pm 29.0\)CRP \(\left(\mathrm {mg}/\mathrm {dl}\right)\)\(2.9\pm 3.0\)\(3.1\pm 3.3\)Swollen joint count \(\left(\mathrm {n}\pm \mathrm {SD}\right)\)0-28\(11.5\pm 4.7\)\(11.8\pm 5.3\)0-66\(16.5\pm 6.2\)\(17.3\pm 7.7\)Tender joint count \(\left(\mathrm {n}\pm \mathrm {SD}\right)\)0-28\(13.2\pm 5.8\)\(13.2\pm 6.1\)0-68\(20.7\pm 9.4\)\(21.1\pm 10.2\)mTSS\(13.6\pm 22.3\)\(13.6\pm 17.4\)Erosion score\(7.5\pm 11.6\)\(7.3\pm 9.2\)Joint space narrowing score\(6.2\pm 11.4\)\(6.2\pm 9.4\)DAS28-ESR\(6.6\pm 0.9\)\(6.6\pm 1.0\)DAS28-CRP\(5.8\pm 1.0\)\(5.9\pm 1.0\)HAQ-DI score\(1.1\pm 0.7\)\(1.3\pm 0.8\)SDAI score\(40.7\pm 12.0\)\(41.4\pm 13.8\)CDAI score\(37.8\pm 10.9\)\(38.3\pm 12.4\)Physician's global assessment of<br>disease activity±SD (mm)\(65.8\pm 18.4\)\(66.2\pm 18.8\)Patient's global assessment of disease<br>activity±SD (mm)\(64.1\pm 24.8\)\(66.4\pm 23.7\)</table>
+*Data are mean±SD unless otherwise indicated.
+CCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.
+to 2.2-fold increase in the percentage of patients achieving clin-ical remission, across all definitions of clinical remission evalu-ated, versus MTX alone.
+A significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 \((-0.6\pm 0.6\) vs \(-0.4\pm 0.6\) ; \(\mathrm {p}<0.001)\) . Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functional-ity (HAQ-DI score\(<0.5)\) after 26 weeks of treatment was also sig-nificantly higher with adalimumab+MTX (figure 3F).
+# Factors associated with the absence of radiographic progression or with clinical remission
+Disease activity or function baseline variables generally were associated with the absence of radiographic progression \(\left(\mathrm {mTSS}\leq 0.5\right)\) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).

stage1/sample_00009/raw_response.md ADDED Viewed

	@@ -0,0 +1,44 @@

+24 baseline demographics and disease characteristics. Significant \((p<0.1)\) variables in univariate were included in multivariate models. Last, multivariate models were selected based on model fit statistics (Akaike information criterion and \(\mathrm {r}^{2})\) and clinical significance. Adjusted OR and \(95\%\) CIs for selected baseline variables were calculated.
+title[[67, 177, 130, 190]]
+# RESULTS
+text[[67, 192, 488, 368]]
+Overall, 334 patients were randomised to treatment and received adalimumab+MTX \(\mathrm {n}=171)\) or MTX alone \(\left(\mathrm {n}=163\right)\) ,and 148 \((86.5\%)\) and 128 \((78.5\%)\) patients completed the double-blind portion of the study, respectively (figure 1).Demographics and baseline characteristics were well matched between treatment groups (table 1). The mean RA disease duration was 0.3 years, and the majority of patients had \(\geq 1\) erosion at baseline and high disease activity. The mean MTX dose during the 26-week study was \(6.2\pm 0.8\mathrm {\sim mg}/\mathrm {week}\) in the adalimumab+MTX group and \(6.6\pm 0.6\mathrm {\sim mg}/\mathrm {week}\) in the MTX alone group \((p<0.001)\) . After 26 weeks of treatment, \(34.5\%\) \((59/171)\) of adalimumab+MTX patients were receiving MTX 8 mg/week versus \(65.0\%\) (106/163) of MTX alone patients \((p<0.001)\) .
+title[[67, 383, 243, 396]]
+# Radiographic progression
+text[[67, 398, 488, 675]]
+Treatment with adalimumab+MTX significantly inhibited radiographic progression (figure 2A) at week 26 versus MTX alone (mean change±SD, \(1.5\pm 6.1\) vs \(2.4\pm 3.2\) , respectively; \(p<0.001)\) . Results were confirmed by an LE analysis (figure 2A). Changes in radiographic progression during 26 weeks of treatment were also assessed by a cumulative probability plot of \(\Delta \mathrm {mTSS}\)  (figure 2B). Fewer adalimumab+MTX patients exhibited radiographic progression \((\Delta \mathrm {mTSS}>0.5)\) ,with \(62.0\%\) (106/171) of patients showing no radiographic progression versus \(35.4\%\) (57/161) of MTX alone patients \((p<0.001)\) .Furthermore, only \(14.0\%\) (24/171) of adalimumab+MTX patients exhibited clinically relevant radiographic progression \((\Delta \mathrm {mTSS}>3)\) versus \(37.3\%\) (60/161) of MTX alone patients \((p<0.001)\) . In addition, a significantly higher percentage of adalimumab+MTX patients did not experience worsening \((\leq 0.5)\) in erosion score ( \(73.7\%\) (126/171)) versus MTX alone patients \((42.2\%\) (68/161); \(p<0.001)\) . In patients who lacked baseline erosive damage, the continued absence of erosions was reported in more adalimumab+MTX patients versus MTX alone patients \((9/9\) vs 2/6 patients, respectively; \(p=0.01)\) .
+title[[67, 691, 185, 703]]
+# Clinical response
+text[[67, 706, 488, 950]]
+A significantly higher percentage of adalimumab+MTX patients achieved ACR responses versus MTX alone patients at each assessment (figure 3A-C). Significant differences between treatment groups, observed as early as week 2, were maintained through week 26. At week 26, a significantly larger percentage of adalimumab+MTX patients versus MTX alone patients achieved ACR20, ACR50 and ACR70 (figure 3A-C) and ACR90 ( \(12.9\%\) vs \(5.5\%\) ; \(p=0.02)\)  responses. Significant differences in favour of adalimumab+MTX were also observed from week 2 to 26 for DAS28-ESR, DAS28-CRP, SDAI and CDAI (see online supplementary figure 1A-D). A larger percentage of adalimumab+MTX patients than MTX alone patients demonstrated good or moderate European League Against Rheumatism responses (figure 3D) and were in states of low disease activity or remission after 26 weeks of treatment (figure 3E). Furthermore, a significantly larger percentage of adalimumab+MTX patients versus MTX alone patients satisfied Boolean remission criteria ( \(19.3\%\) vs \(8.6\%\) , \(p=0.007)\) . Adalimumab+MTX achieved a 1.8-
+table_caption[[524, 75, 829, 88]]
+Table 1 Demographics and baseline characteristics
+table[[519, 91, 920, 561]]
+<table>Parameter*Adalimumab+MTX<br>\(\left(\mathrm {n}=171\right)\)MTX \(\left(\mathrm {n}=163\right)\)\(\text {Age}\pm \mathrm {SD}\) (year)\(54.0\pm 13.1\)\(54.0\pm 13.2\)Females \(\left(\% \right)\)144 (84.2)128 (78.5)RA duration\(\pm \mathrm {SD}\) (year)\(0.3\pm 0.4\)\(0.3\pm 0.4\)Weight\(\pm \mathrm {SD}\) (kg)\(54.4\pm 9.7\)\(56.1\pm 12.3\)Previous DMARD use \(\left(\% \right)\)74 (43.3)87 (53.4)1 DMARD57 (33.3)69 (42.3)2 DMARDs17 (9.9)18 (11.0)Corticosteroid use at baseline \(\left(\% \right)\)58 (33.9)49 (30.1)RF positive \(\left(\% \right)\)146 (85.4)136 (83.4)Mean titre±SD (IU/ml)\(154.5\pm 202.3\)\(163.7\pm 362.8\)Anti-CCP positive \(\left(\% \right)\)145 (84.8)136 (83.4)Mean titre±SD (U/ml)\(386.2\pm 694.2\)\(241.3\pm 367.2\)ESR \(\left(\mathrm {mm}/\mathrm {h}\right)\)\(59.9\pm 30.1\)\(61.8\pm 29.0\)CRP \(\left(\mathrm {mg}/\mathrm {dl}\right)\)\(2.9\pm 3.0\)\(3.1\pm 3.3\)Swollen joint count \(\left(\mathrm {n}\pm \mathrm {SD}\right)\)0-28\(11.5\pm 4.7\)\(11.8\pm 5.3\)0-66\(16.5\pm 6.2\)\(17.3\pm 7.7\)Tender joint count \(\left(\mathrm {n}\pm \mathrm {SD}\right)\)0-28\(13.2\pm 5.8\)\(13.2\pm 6.1\)0-68\(20.7\pm 9.4\)\(21.1\pm 10.2\)mTSS\(13.6\pm 22.3\)\(13.6\pm 17.4\)Erosion score\(7.5\pm 11.6\)\(7.3\pm 9.2\)Joint space narrowing score\(6.2\pm 11.4\)\(6.2\pm 9.4\)DAS28-ESR\(6.6\pm 0.9\)\(6.6\pm 1.0\)DAS28-CRP\(5.8\pm 1.0\)\(5.9\pm 1.0\)HAQ-DI score\(1.1\pm 0.7\)\(1.3\pm 0.8\)SDAI score\(40.7\pm 12.0\)\(41.4\pm 13.8\)CDAI score\(37.8\pm 10.9\)\(38.3\pm 12.4\)Physician's global assessment of<br>disease activity±SD (mm)\(65.8\pm 18.4\)\(66.2\pm 18.8\)Patient's global assessment of disease<br>activity±SD (mm)\(64.1\pm 24.8\)\(66.4\pm 23.7\)</table>
+text[[524, 571, 920, 650]]
+*Data are mean±SD unless otherwise indicated.
+text[[524, 574, 920, 650]]
+CCP, cyclic citrullinated peptide; CDAI, clinical disease activity index; CRP, C reactive protein; DAS28-CRP, disease activity score using a 28-joint count and CRP level; DAS28-ESR, disease activity score using a 28-joint count and ESR; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire disability index; mTSS, modified total Sharp score; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, simplified disease activity index.
+text[[513, 680, 930, 720]]
+to 2.2-fold increase in the percentage of patients achieving clin-ical remission, across all definitions of clinical remission evalu-ated, versus MTX alone.
+text[[513, 722, 930, 825]]
+A significantly larger decrease from baseline in mean HAQ-DI score, indicative of an improvement in physical function, was observed for adalimumab+MTX patients versus MTX alone patients at week 26 \((-0.6\pm 0.6\) vs \(-0.4\pm 0.6\) ; \(\mathrm {p}<0.001)\) . Although the significant difference between the two groups was small (0.2 units), the percentage of patients achieving normal functional-ity (HAQ-DI score\(<0.5)\) after 26 weeks of treatment was also sig-nificantly higher with adalimumab+MTX (figure 3F).
+title[[513, 856, 862, 883]]
+# Factors associated with the absence of radiographic progression or with clinical remission
+text[[513, 885, 930, 952]]
+Disease activity or function baseline variables generally were associated with the absence of radiographic progression \(\left(\mathrm {mTSS}\leq 0.5\right)\) and with clinical remission (DAS28-ESR<2.6) in both treatment groups (see online supplementary text and online supplementary table 1).

stage1/sample_00009/source.png ADDED Viewed

Git LFS Details

SHA256: 54803905f6e29be8e4b6411bacd6fc58b91f54a126c9a40f795c1cfb54040d25
Pointer size: 131 Bytes
Size of remote file: 751 kB

stage1/sample_00010/document.md ADDED Viewed

	@@ -0,0 +1 @@

+ 1995;38:44-8. 22 Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45. 23 Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57. 24 Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806. 25 van Gestel AM, Prevoo MLL, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40. 26 Wells G, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009;68:954-60. 27 Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404-13. 28 Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 suppl 39):S100-8.

stage1/sample_00010/raw_response.md ADDED Viewed

	@@ -0,0 +1 @@

stage1/sample_00010/source.png ADDED Viewed

Git LFS Details

SHA256: 4191fa83b029f4f114926153f73abf248b70435e21647585947990dbf2bf6a46
Pointer size: 131 Bytes
Size of remote file: 167 kB

stage1/sample_00011/document.md ADDED Viewed

	@@ -0,0 +1 @@

+ 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0

stage1/sample_00011/raw_response.md ADDED Viewed

	@@ -0,0 +1 @@

stage1/sample_00011/source.png ADDED Viewed

Git LFS Details

SHA256: 2bb57301a3d3b80224539cac2dbb97a72fb212d76ca7e5a6c6fec4dbe46aee51
Pointer size: 131 Bytes
Size of remote file: 827 kB

stage1/sample_00012/document.md ADDED Viewed

	@@ -0,0 +1 @@


1	+ Local transportation for the participating teams shall be the responsibility of the participating institutions.

stage1/sample_00012/raw_response.md ADDED Viewed

	@@ -0,0 +1 @@


1	+ Local transportation for the participating teams shall be the responsibility of the participating institutions.

stage1/sample_00012/source.png ADDED Viewed

Git LFS Details

SHA256: 801bfb8d18eb981b656f399875f84000cf40b3f110795241750f054ca65c3958
Pointer size: 131 Bytes
Size of remote file: 388 kB

stage1/sample_00013/document.md ADDED Viewed

	@@ -0,0 +1,29 @@

+![Figure sample_00013_fig01](figures/sample_00013_fig01.png)
+# SECTION VI: SCHEDULE OF EVENTS
+# Friday
+Course preparation.
+Course walk-through with NCAA site representative.
+Course review and practice by participants.
+Packet pick-up.
+Mandatory coaches meeting.
+# Saturday
+Course preparation.
+Course review and practice by participants.
+Women's race - race start time to be determined.*
+Men's race - race start time to be determined.*
+Post-competition recognition ceremony.
+*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.

stage1/sample_00013/figures/sample_00013_fig01.png ADDED Viewed

Git LFS Details

SHA256: 313fc06d4e96ad5776e0332780bebb01441ca456e1e84f2fa1085b5a97993bb8
Pointer size: 130 Bytes
Size of remote file: 98.8 kB

stage1/sample_00013/raw_response.md ADDED Viewed

	@@ -0,0 +1,43 @@

+image[[117, 42, 881, 199]]
+title[[571, 214, 883, 230]]
+# SECTION VI: SCHEDULE OF EVENTS
+title[[122, 254, 171, 266]]
+# Friday
+text[[122, 271, 256, 283]]
+Course preparation.
+text[[122, 286, 463, 298]]
+Course walk-through with NCAA site representative.
+text[[122, 302, 406, 314]]
+Course review and practice by participants.
+text[[122, 318, 226, 330]]
+Packet pick-up.
+text[[122, 334, 314, 346]]
+Mandatory coaches meeting.
+title[[122, 366, 190, 377]]
+# Saturday
+text[[122, 382, 256, 394]]
+Course preparation.
+text[[122, 398, 406, 410]]
+Course review and practice by participants.
+text[[122, 414, 453, 426]]
+Women's race - race start time to be determined.*
+text[[122, 430, 434, 442]]
+Men's race - race start time to be determined.*
+text[[122, 446, 385, 458]]
+Post-competition recognition ceremony.
+text[[122, 477, 874, 507]]
+*The men's race will go first in even years, the women's race will go first in odd years. Start times are subject to the approval of the track and field and cross country committee.

stage1/sample_00013/source.png ADDED Viewed

Git LFS Details

SHA256: 8d5431b40f60286b5503572904171775da3ad50d3ea55fdef575c1e1a9922cb1
Pointer size: 131 Bytes
Size of remote file: 360 kB

stage1/sample_00014/document.md ADDED Viewed

	@@ -0,0 +1,7 @@

+75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales.
+The prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting "Yes" below.
+YES NO NO with Exception
+Prospective hosts who do not agree with all requirements in this document shall select either "No" or "No with Exception" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.

stage1/sample_00014/raw_response.md ADDED Viewed

	@@ -0,0 +1,10 @@

+75- 150 volunteers on competition day will be needed for assignments, including course safety, finish chute, concessions, parking, media and merchandise sales.
+text[[124, 619, 883, 699]]
+The prospective host that is bidding on this championship agrees to all terms and conditions as outlined above in this Championship Bid Specifications Agreement. We agree to comply with all the requirements listed in this document and to administer the designated championship in accordance with the policies of the NCAA and the applicable NCAA sports committee. Prospective hosts that agree with all the requirements listed in this document for the designated championship shall signify agreement by selecting "Yes" below.
+text[[312, 712, 698, 731]]
+YES NO NO with Exception
+text[[130, 745, 883, 809]]
+Prospective hosts who do not agree with all requirements in this document shall select either "No" or "No with Exception" and declare any issues and/or exceptions regarding the aforementioned terms. Please note: any proposed revisions to the language in this document must be specified in the bidding portal to be considered.

stage1/sample_00014/source.png ADDED Viewed

Git LFS Details

SHA256: b0baa7e8133f1e40010c81584f521792731f78cb50bac55e205f5b95fbd668be
Pointer size: 131 Bytes
Size of remote file: 393 kB

stage1/sample_00015/document.md ADDED Viewed

	@@ -0,0 +1,9 @@

+145 (Fig. 6B), which over-express EGFR (Fig. 6C).
+![Figure sample_00015_fig01](figures/sample_00015_fig01.png)
+In summary, our data show that SR48692 selectively sensitizes PC cells to ionizing radiation. Our results also show that NT stimulation (a) activates a novel EGFR/Src/Stat5b signaling pathway and enhances PC cell proliferation and (b) stabilizes the androgen receptor (AR) through EGFR/Src - dependent phosphorylation; both of which can be inhibited by SR48692. Activation of the EGFR, Src and AR pathway(s) has been implicated, not only in the development of androgen- independent disease, but also in tumor metastasis, especially in bones. Future research, planned for the third and final year of this project, will concentrate on animal studies (completing Task 2 and 3), the role(s) of neuroendocrine cell secretions (Task 1c), and will finalize studies on molecular mechanisms of SR48692 radiosensitizing activity (Task 4). In addition, Cetuximab (C-225/Erbitux, ImClone), a clinically used EGFR inhibitor, will be used to study the role of EGFR in SR- induced radiosensitization. We speculate that inhibitors, such as Cetuximab or Dasatinib (Bristol- Myers- Squibb; a Src family inhibitor), will significantly improve experimental radiotherapy outcome and could establish the basis for future combined treatment therapy in humans.
+## KEY RESEARCH ACCOMPLISHMENTS
+- We have demonstrated that radiosensitizing activity of SR48692 depends on the expression of NTR1 receptor in prostate cells. This establishes the foundation of cancer-specificity of SR48692 radiosensitizing activity.- We have demonstrated that radiosensitizing activity of SR48692 is not dependent on androgen receptor (AR) expression levels in prostate cells. However, SR48692 blocks neurotensin-induced AR phosphorylation/stabilization. Therefore, blocking NTR1 receptor could provide additional benefits to anti-tumor therapy.- We have demonstrated that the radiosensitizing activity of SR48692 is affected by the EGFR receptor levels in prostate cells.

stage1/sample_00015/figures/sample_00015_fig01.png ADDED Viewed

Git LFS Details

SHA256: 00f3de58056cf3d633c3d68b0c4adf9a6972b73216e8bd449234edc7f78d0980
Pointer size: 130 Bytes
Size of remote file: 48.8 kB

stage1/sample_00015/raw_response.md ADDED Viewed

	@@ -0,0 +1,12 @@

+145 (Fig. 6B), which over-express EGFR (Fig. 6C).
+image[[57, 95, 608, 430]]
+text[[56, 445, 937, 664]]
+In summary, our data show that SR48692 selectively sensitizes PC cells to ionizing radiation. Our results also show that NT stimulation (a) activates a novel EGFR/Src/Stat5b signaling pathway and enhances PC cell proliferation and (b) stabilizes the androgen receptor (AR) through EGFR/Src - dependent phosphorylation; both of which can be inhibited by SR48692. Activation of the EGFR, Src and AR pathway(s) has been implicated, not only in the development of androgen- independent disease, but also in tumor metastasis, especially in bones. Future research, planned for the third and final year of this project, will concentrate on animal studies (completing Task 2 and 3), the role(s) of neuroendocrine cell secretions (Task 1c), and will finalize studies on molecular mechanisms of SR48692 radiosensitizing activity (Task 4). In addition, Cetuximab (C-225/Erbitux, ImClone), a clinically used EGFR inhibitor, will be used to study the role of EGFR in SR- induced radiosensitization. We speculate that inhibitors, such as Cetuximab or Dasatinib (Bristol- Myers- Squibb; a Src family inhibitor), will significantly improve experimental radiotherapy outcome and could establish the basis for future combined treatment therapy in humans.
+sub_title[[57, 706, 420, 723]]
+## KEY RESEARCH ACCOMPLISHMENTS
+text[[84, 733, 939, 906]]
+- We have demonstrated that radiosensitizing activity of SR48692 depends on the expression of NTR1 receptor in prostate cells. This establishes the foundation of cancer-specificity of SR48692 radiosensitizing activity.- We have demonstrated that radiosensitizing activity of SR48692 is not dependent on androgen receptor (AR) expression levels in prostate cells. However, SR48692 blocks neurotensin-induced AR phosphorylation/stabilization. Therefore, blocking NTR1 receptor could provide additional benefits to anti-tumor therapy.- We have demonstrated that the radiosensitizing activity of SR48692 is affected by the EGFR receptor levels in prostate cells.